How to buy Century Therapeutics stock | $19.31

Century Therapeutics Inc. is a biotechnology business based in the US. Century Therapeutics shares (IPSC) are listed on the NASDAQ and all prices are listed in US Dollars. Century Therapeutics employs 121 staff and has a market cap (total outstanding shares value) of 0.00.

Century Therapeutics stock price (NASDAQ: IPSC)

Use our graph to track the performance of IPSC stocks over time.

Century Therapeutics shares at a glance

• Key figures

Information last updated 2021-10-10.

Latest market close	$19.31
52-week range	$17.53 - $32.90
50-day moving average	$24.19
200-day moving average	$26.45
Wall St. target price	$36.25
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-8.14

Buy Century Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Century Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Century Therapeutics price performance over time

Historical closes compared with the close of $19.31 from 2021-10-15

1 week (2021-10-08)	8.91%
1 month (2021-09-17)	-22.01%
3 months (2021-07-16)	-29.93%
6 months (2021-04-13)	N/A

1 year (2020-10-13)	N/A
2 years (2019-10-13)	N/A
3 years (2018-10-13)	N/A
5 years (2016-10-13)	N/A

Century Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	0%
Return on equity TTM	0%
Profit margin	0%
Book value	$8.23
Market capitalisation	$964.6 million

TTM: trailing 12 months

Shorting Century Therapeutics shares

There are currently 1.6 million Century Therapeutics shares held short by investors – that's known as Century Therapeutics's "short interest". This figure is 6.3% down from 1.7 million last month.

There are a few different ways that this level of interest in shorting Century Therapeutics shares can be evaluated.

Century Therapeutics's "short interest ratio" (SIR)

Century Therapeutics's "short interest ratio" (SIR) is the quantity of Century Therapeutics shares currently shorted divided by the average quantity of Century Therapeutics shares traded daily (recently around 154649.6124031). Century Therapeutics's SIR currently stands at 10.32. In other words for every 100,000 Century Therapeutics shares traded daily on the market, roughly 10320 shares are currently held short.

To gain some more context, you can compare Century Therapeutics's short interest ratio against those of similar companies.

• Prelude Therapeutics Incorporated (PRLD.US): 10.76
• Greenwich LifeSciences (GLSI.US): 4.03
• Pfizer (PFE.US): 1.98

However Century Therapeutics's short interest can also be evaluated against the total number of Century Therapeutics shares, or, against the total number of tradable Century Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Century Therapeutics's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Century Therapeutics shares in existence, roughly 30 shares are currently held short) or 0.1074% of the tradable shares (for every 100,000 tradable Century Therapeutics shares, roughly 107 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Century Therapeutics.

Find out more about how you can short Century Therapeutics stock.

Century Therapeutics share dividends

We're not expecting Century Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

• Pfizer (PFE.US) (3.7% forward annual dividend yield)

Century Therapeutics overview

Century Therapeutics, Inc. , a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. Century Therapeutics, Inc. has a research collaboration with Outpace Bio, Inc. for CAR engineering.

Frequently asked questions

What percentage of Century Therapeutics is owned by insiders or institutions?
Currently 11.226% of Century Therapeutics shares are held by insiders and 41.184% by institutions. How many people work for Century Therapeutics?
Latest data suggests 121 work at Century Therapeutics. When does the fiscal year end for Century Therapeutics?
Century Therapeutics's fiscal year ends in December. Where is Century Therapeutics based?
Century Therapeutics's address is: 3675 Market Street, Philadelphia, PA, United States, 19104 What is Century Therapeutics's ISIN number?
Century Therapeutics's international securities identification number is: US15673T1007